XML 28 R19.htm IDEA: XBRL DOCUMENT

Grant Revenue	9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Grant Revenue	12. Grant revenue In July 2022, the Company entered into a new partnership with CEPI to advance our exoVACC pan betacoronavirus program. As part of the partnership, CEPI is providing seed funding of up to $2.5 million, which the Company anticipates will fund the completion of preclinical development and identification of a clinical candidate by early 2023. All funding received from CEPI must be used for preclinical studies, assessing the immune response against known Betacoronaviruses that already pose a significant epidemic or pandemic risk, such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV, and the potential of the immune response to protect against infection and disease caused by these viruses. As of September 30, 2022, the Company has received $1.6 million in grants. During both the three and nine months ended September 30, 2022, the Company recognized $0.5 million in grant revenue under its partnership with CEPI. As of September 30, 2022, the Company had $1.1 million in deferred revenue with respect to its partnership with CEPI.

Grant Revenue

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

12. Grant revenue

In July 2022, the Company entered into a new partnership with CEPI to advance our exoVACC pan betacoronavirus program. As part of the partnership, CEPI is providing seed funding of up to $2.5 million, which the Company anticipates will fund the completion of preclinical development and identification of a clinical candidate by early 2023. All funding received from CEPI must be used for preclinical studies, assessing the immune response against known Betacoronaviruses that already pose a significant epidemic or pandemic risk, such as SARS-CoV-1, SARS-CoV-2, and MERS-CoV, and the potential of the immune response to protect against infection and disease caused by these viruses. As of September 30, 2022, the Company has received $1.6 million in grants.

During both the three and nine months ended September 30, 2022, the Company recognized $0.5 million in grant revenue under its partnership with CEPI. As of September 30, 2022, the Company had $1.1 million in deferred revenue with respect to its partnership with CEPI.